Northern Irish drugmaker Galen Holdings Plc said today it had reached an agreement with Bristol-Myers Squibb to co-promote Dovonex, a treatment for the skin disease psoriasis licensed by Denmark's LEO Pharma.
Galen also said it had agreed to license Dovobet, LEO Pharma's experimental treatment for psoriasis, for $47 million.